QuidelOrtho [QDEL] vs Abbott Laboratories [ABT] Detailed Stock Comparison
QuidelOrtho
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: QuidelOrtho wins in 8 metrics, Abbott Laboratories wins in 10 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | QuidelOrtho | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.92 | 16.69 | QuidelOrtho |
| Price-to-Book Ratio | 0.67 | 4.58 | QuidelOrtho |
| Debt-to-Equity Ratio | 100.33 | 26.50 | Abbott Laboratories |
| PEG Ratio | -0.01 | 0.46 | QuidelOrtho |
| EV/EBITDA | 7.82 | 20.78 | QuidelOrtho |
| Profit Margin (TTM) | -17.01% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -0.73% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -15.64% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 1.36% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-112.10M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -32.13% | 15.63% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 0.69 | 5.40 | QuidelOrtho |
| Enterprise Value | $4.53B | $237.97B | Abbott Laboratories |
| EV/Revenue Ratio | 1.65 | 5.52 | QuidelOrtho |
| Gross Profit Margin (TTM) | 44.78% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $41 | $25 | QuidelOrtho |
| Earnings per Share (Diluted) | $-6.84 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 0.27 | 0.70 | QuidelOrtho |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
QuidelOrtho vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| QuidelOrtho | 0.54% | -10.85% | -2.14% | -9.60% | 6.34% | -38.14% |
| Abbott Laboratories | 0.94% | 0.60% | 1.57% | 0.68% | 8.33% | 18.36% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| QuidelOrtho | -32.13% | -63.48% | -89.09% | 52.16% | 124.86% | 166.35% |
| Abbott Laboratories | 15.63% | 33.06% | 22.43% | 218.02% | 426.34% | 556.26% |
News Based Sentiment: QuidelOrtho vs Abbott Laboratories
QuidelOrtho
News based Sentiment: MIXED
October presented a complex picture for QuidelOrtho, with positive industry tailwinds offset by analyst downgrades, increased debt costs, and concerns about revenue exposure to China. While the company is focused on improving efficiency and launching new products, the overall narrative is one of significant challenges and uncertainties, making it a mixed investment story.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories delivered strong Q2 earnings and raised guidance, leading to positive analyst revisions and continued institutional investment. While some valuation models suggest the stock may be overvalued, the overall narrative is positive, driven by strong financial performance and a promising product pipeline.
Performance & Financial Health Analysis: QuidelOrtho vs Abbott Laboratories
| Metric | QDEL | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.89B | $231.52B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 1,487,820 | 5,842,290 |
| 90 Day Avg. Volume | 1,319,670 | 5,589,430 |
| Last Close | $27.86 | $134.27 |
| 52 Week Range | $22.05 - $49.45 | $110.86 - $141.23 |
| % from 52W High | -43.66% | -4.93% |
| All-Time High | $306.72 (Aug 03, 2020) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -90.92% | -5.84% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | 0.07% |
| Quarterly Earnings Growth | -0.04% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.17% | 0.32% |
| Operating Margin (TTM) | -0.01% | 0.20% |
| Return on Equity (TTM) | -0.16% | 0.31% |
| Debt to Equity (MRQ) | 100.33 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $41.25 | $29.05 |
| Cash per Share (MRQ) | $2.25 | $4.18 |
| Operating Cash Flow (TTM) | $200.40M | $9.04B |
| Levered Free Cash Flow (TTM) | $410.38M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: QuidelOrtho vs Abbott Laboratories
| Metric | QDEL | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.92 | 16.69 |
| Forward P/E | 10.45 | 25.78 |
| PEG Ratio | -0.01 | 0.46 |
| Price to Sales (TTM) | 0.69 | 5.40 |
| Price to Book (MRQ) | 0.67 | 4.58 |
| Market Capitalization | ||
| Market Capitalization | $1.89B | $231.52B |
| Enterprise Value | $4.53B | $237.97B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.65 | 5.52 |
| Enterprise to EBITDA | 7.82 | 20.78 |
| Risk & Other Metrics | ||
| Beta | 0.27 | 0.70 |
| Book Value per Share (MRQ) | $41.25 | $29.05 |
Financial Statements Comparison: QuidelOrtho vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QDEL | ABT |
|---|---|---|
| Revenue/Sales | $613.90M | $10.36B |
| Cost of Goods Sold | $339.00M | $4.47B |
| Gross Profit | $274.90M | $5.89B |
| Research & Development | $45.70M | $716.00M |
| Operating Income (EBIT) | $-1.80M | $1.69B |
| EBITDA | $100.00M | $2.66B |
| Pre-Tax Income | $-229.60M | $1.78B |
| Income Tax | $25.80M | $453.00M |
| Net Income (Profit) | $-255.40M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QDEL | ABT |
|---|---|---|
| Cash & Equivalents | $127.10M | $6.53B |
| Total Current Assets | $1.26B | $23.15B |
| Total Current Liabilities | $1.05B | $13.00B |
| Long-Term Debt | $2.27B | $12.74B |
| Total Shareholders Equity | $3.00B | $49.06B |
| Retained Earnings | $123.10M | $47.72B |
| Property, Plant & Equipment | $2.35B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QDEL | ABT |
|---|---|---|
| Operating Cash Flow | $41.90M | $1.42B |
| Capital Expenditures | $-56.20M | $-484.00M |
| Free Cash Flow | $9.40M | $933.00M |
| Debt Repayment | $-36.00M | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | QDEL | ABT |
|---|---|---|
| Shares Short | 8.15M | 18.07M |
| Short Ratio | 7.03 | 3.68 |
| Short % of Float | 0.20% | 0.01% |
| Average Daily Volume (10 Day) | 1,487,820 | 5,842,290 |
| Average Daily Volume (90 Day) | 1,319,670 | 5,589,430 |
| Shares Outstanding | 67.26M | 1.73B |
| Float Shares | 62.65M | 1.73B |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.17% | 0.81% |
Dividend Analysis & Yield Comparison: QuidelOrtho vs Abbott Laboratories
| Metric | QDEL | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |